Table 2.

Treatment characteristics and response (n = 11)

Patients	Induction phase		Consolidation phase		Relapse	Survival
	Regimen	Response	Regimen	Response	mo	mo	Status
1	CHOP	Failure	–	–	–	3	DOD
2	CHOP	Failure	–	–	–	2	DOD
3	CHOP–bortezomib	PR	CT+ RT	PR	20	48	Alive
4	CHOP–bortezomib	Failure	–	–	–	8	DOD
5	CHOP– Chidamide	CR	AlloHCT	CR	–	10	Alive
6	GDP	PR	CT	Failure	–	10	DOD
7	IVAC	CR	CT	CR	21	25	Alive
8	VDCLP	PR	AlloHCT	CR	–	27	Alive
9	Hyper-CVAD	SD	AlloHCT	CR	10	11	DOD
10	DEP	Failure	–	–	–	3	DOD
11	DHAP	CR	AlloHCT	CR	–	12	Alive

DOD died of disease, CR complete remission, PR partial remission, SD stable disease, CT chemotherapy, RT radiotherapy, CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, GDP gemcitabine, cisplatin, dexamethasone, VDCLP vincristine, doxorubicin, cyclophosphamide, l-asparaginase, prednisone, Hyper-CVAD cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, AlloHCT allogeneic hematopoietic cell transplantation, DEP dexamethasone, etoposide, doxorubicin, DHAP dexamethasone, cisplatin, cytarabine